Worse Survival Seen With Tumor-Infiltrating Clonal Hematopoiesis in Patients With Solid Tumors

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 15, 2026.

via HealthDay

FRIDAY, May 15, 2026 -- Tumor-infiltrating clonal hematopoiesis (TI-CH) is associated with worse survival among patients with solid tumors, according to a study published online May 7 in JAMA Oncology.

Dabin Yun, Pharm.D., from Chungbuk National University in South Korea, and colleagues characterized the prevalence of TI-CH in solid tumors and assessed its association with clinical factors and overall survival in a retrospective cohort study analyzing whole-genome sequencing data of a large cohort of patients with solid tumors. The prevalence of TI-CH was measured as the primary outcome, defined by somatic variants in 74 driver genes in tumor tissue.

The researchers found that TI-CH was detected in 1,943 of 10,571 patients with solid tumors (18.38 percent), with the highest frequency among patients with TET2 variants and in those with endometrial cancer (212 and 251 patients, respectively). TI-CH was more common with older age and cytotoxic chemotherapy (odds ratios, 1.15 and 1.24, respectively). There was a significant association seen for TI-CH with worse pan-cancer overall survival, particularly breast cancer overall survival (hazard ratios, 1.13 and 1.95, respectively). Worse pan-cancer overall survival was significantly associated with GATA2 variants, while worse breast cancer overall survival was significantly associated with TET2 variants (hazard ratios, 3.00 and 2.92, respectively).

"These findings underscore the clinical potential of TI-CH as a prognostic biomarker in patients with solid tumors," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-16 02:24

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords